Disposition and metabolism of almotriptan in rats, dogs and monkeys

Xenobiotica

Volumn 36, Issue 9, 2006, Pages 807-823

  Aubets, J ^a   Cardenas, A ^a   Salva, M ^a   Jansat, J M ^a   Martinez Tobed, A ^a   Palacios, J M ^a  

^a Almirall Prodesfarma SA ^*  (Spain)

Author keywords

Almotriptan; Deamination; Disposition; N oxidation; Pyrrolidine ring oxidation

Indexed keywords

4 AMINOBUTYRIC ACID; ALMOTRIPTAN; CARBON 14; DRUG METABOLITE; INDOLEACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE; DEAMINATION; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FECES; FEMALE; FIRST PASS EFFECT; MALE; MONKEY; NONHUMAN; OXIDATION; RADIOACTIVITY; RAT; URINARY EXCRETION; URINE;

ANIMALS; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG ADMINISTRATION ROUTES; FEMALE; HAPLORHINI; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGONISTS; SEROTONIN RECEPTOR AGONISTS; TRYPTAMINES;

ANIMALIA; CANIS FAMILIARIS;

EID: 33748695059     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600802508     Document Type: Article

References (25)

1. Aronson JK, Dengler HJ, Dettli L, Follath F. 1988. Standardization of symbols in clinical pharmacology. European Journal of Clinical Pharmacology 35:1-7.
2. Bou J, Domenech T, Puig J, Heredia A, Gras J, Fernandez-Forner D, Beleta J, Palacios JM. 2000. Pharmacological characterization of almotriptan: An indolic 5-HT receptor agonist for the treatment of migraine. European Journal of Pharmacology 410:33-41.
3. Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. 2001. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalgia 21:804-812.
4. Buchan P, Wade A, Ward C, Oliver SD, Stewart AJ, Freestone S. 2002. Frovatriptan: A review of drug-drug interactions. Headache 42(Suppl. 2):S63-S73.
5. Cabarrocas X, Esbri R, Peris F, Ferrer P. 2001. Long-term efficacy and safety of oral almotriptan: Interim analysis of a 1-year open study. Headache 41:57-62.
6. Committee for Pharmacokinetic Nomenclature of the American College of Clinical Pharmacology. 1982. Manual of symbols, equations and definitions in Pharmacokinetics. Journal of Clinical Pharmacology 22:1S-23S.
7. Dixon CM, Park GR, Tarbit MH. 1994. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochemical and Pharmacology 47:1253-1257.
8. Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbeyrt A, Tarbit MH. 1993. Disposition of sumatriptan in laboratory animals and humans. Drug Metabolism and Disposition 21:761-769.
9. Dodick DW. 2001. Oral almotriptan in the treatment of migraine: Safety and tolerability. Headache 41:449-455.
10. Dodick DW, Martin V. 2004. Triptans and CNS side-effects: Pharmacokinetic and metabolic mechanisms. Cephalalgia 24:417-424.
11. Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R. 2003. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metabolism and Disposition 31(7):861-869.
12. Ferrari MD, Saxena PR. 1995. 5-HT1 receptors in migraine pathophysiology and treatment. European Journal of Neurology 2:5-21.
13. Gras J, Bou J, Llenas J, Fernandez AG, Palacios JM. 2000a. Functional profile of almotriptan in animal models predictive of antimigraine activity. European Journal of Pharmacology 410:43-51.
14. Gras J, Cardelus I, Llenas J, Palacios JM. 2000b. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine. European Journal of Pharmacology 410:53-59.
15. Jansat JM, Costa J, Salva P, Fernandez FJ, Martinez-Tobed A. 2002. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. Journal of Clinical Pharmacology 42:1303-1310.
16. Mathew NT. 1999. Naratriptan: A review. Expert Opinions in Investigational Drugs 8:687-695.
17. Milton KA, Scott NR, Allen MJ, Abel S, Jenkins VC, James GC, Rance DJ, Eve MD. 2002. pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration. Journal of Clinical Pharmacology 42(5):528-539.
18. Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P, Robert M, Ferrer P, Luria X, Segarra R, Zayas JM. 2000. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study. Cephalgia 20:588-596.
19. Perry CM, Markham A. 1998. Sumatriptan. An updated review of its use in migraine. Drugs 55:889-922.
20. Salva M, Jansat JM, Martinez-Tobed A, Palacios P. 2003. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metabolism and Disposition 31:404-411.
21. Seaber EJ, Peck RW, Smith DA, Allanson J, Hefting NR, Van Lier JJ, Sollie FA, Wemer J, Jonkman JH. 1998. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. British Journal of Clinical Pharmacology 48:433-439.
22. Ullberg S, Larsson B. 1981. Whole-body autoradiography. Methods in Enzymology 77:64-80.
23. Vyas KP, Halpin RA, Geer LA, Ellis JD, Liu L, Cheng H, Chavez-Eng C, Matuszewski BK, Varga SL, Guiblin AR, Rogers JD. 2000. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metabolism and Disposition 28:89-95.
24. Wild MJ, McKillop D, Butters CJ. 1999. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica 29:847-885.
25. Yates RA, Tateno M, Nairn K, Ikegami A, Dane A, Kemp J. 2002. The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects. European Journal of Clinical Pharmacology 58(4):247-252.